Sort   by:  
 Page size 
ProteomicsTemperature induced change of the HLA ligandome
Temperature induced change of the HLA ligandome and proteome in B-cells
ORGANISM(S): Homo sapiens (Human) 
2021-05-07 | PXD022930 | Pride
Hla class ii ligandome Hla class i ligandome Immunopeptidome Proteome Lc-ms/ms 
ProteomicsThe HLA ligandome comprises a limited repertoire of O-GlcNAcylated antigens preferentially associated with HLA-B07:02
Mass-spectrometry based immunopeptidomics has provided unprecedented insights into antigen presentation, not only charting an enormous ligandome of self-antigens, but also cancer neo-antigens and peptide antigens harbouring post-translational modifications. Here we concentrate on the latter, focusin...
ORGANISM(S): Homo sapiens (Human) 
2021-12-03 | PXD028874 | Pride
O-glcnacylation Hla-b07 Mhc Hla class i Immunopeptidomics 
ProteomicsTumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.
The recent success of monoclonal antibody checkpoint inhibitor therapies that enhance the ability of CD8+ T cells to detect cancer-related antigenic peptides has refocused the need to fully understand the repertoire of peptides being presented to the immune system. Whilst the peptide ligandome prese...
ORGANISM(S): Homo sapiens (Human) 
2022-04-01 | PXD025345 | Pride
Cancer Extracellular vesicles T-cell epitopes Taa Hla class i ligandome Evs Tumour. Tumour-associated antigens 
ProteomicsZapnometinib treatment and influenza A virus infection induce alteration on the HLA class I ligandome of human lung adenocarcinoma cells
Targeting cellular factors is considered a promising approach to combat viral infection and overcome the resistance issue associated with direct-acting antiviral (DAA) drugs administration. In the context of drug repurposing strategies, we have previously explored the antiviral efficacy of the MEK i...
ORGANISM(S): Homo sapiens (Human) 
2026-06-15 | PXD041578 | Pride
Influenza a virus Ligandome analysis Mek inhibitors Zapnometinib Mhc-i Lc-ms/ms 
ProteomicsHLA class I ligandome of colon cancer tissues for neoantigen identification
MS data of HLA class I ligandome of human colon cancer tissues
ORGANISM(S): Homo Sapiens (human) 
PXD026573 | JPOST Repository
ProteomicsHLA class I ligandome of colon cancer tissues for lncRNA antigen identification
MS data of HLA class I ligandome of human colon cancer tissues
ORGANISM(S): Homo Sapiens (human) 
PXD024533 | JPOST Repository
ProteomicsMapping the HLA ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
Immunopeptidome analysis of colorectal adenocarcinoma tissues as well as adjacent benign tissues was performed to characterize the natural HLA class I and class II presented ligandome represented in the context of malignancy as well as in benign tissue of the colon.
ORGANISM(S): Homo sapiens (Human) 
2019-03-12 | PXD009602 | Pride
Neoplasia Cancer Hla-ligandomics Hla Colorectal adenocarcinoma Colon cancer Peptide Hla-restricted peptide Hla-ligand Colon 
ProteomicsCharacterization of the HLA class I Ligandome from Extracellular vesicles
Extracellular vesicles have shown promise in the field of anti-tumor vaccines. EVs are antigen-presenting entities capable of eliciting potent T-cell responses and have therefore being explored as cell-free based peptide vaccine vectors. However, whether the EV ligandome sufficiently resembles the c...
ORGANISM(S): Homo sapiens (Human) 
2021-07-05 | PXD021177 | Pride
Ev vaccines Extracellular vesicles Immunopeptidomics Ligandome Hla-i 
ProteomicsThe HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Anti-leukemia immunity plays an important role for disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Antigen-specific immunotherapy holds promise to strengthen immune control in CML, but requires the identification of CML-associated ...
ORGANISM(S): Homo sapiens (Human) 
2018-12-11 | PXD010450 | Pride
Mass spectrometry Chronic myeloid leukemia Immunopeptidome 
ProteomicsIntra-patient clonal diversity in HLA class I peptide ligand presentation
Tumor heterogeneity results from clonal diversity and evolutionary selection, and is a major cause of therapeutic resistance. Immunotherapy may exploit alternative vulnerabilities of drug resistant cells, and tumor-specific HLA peptide ligands on the cell surface are promising leads to invoke such t...
ORGANISM(S): Homo sapiens (Human) 
2020-10-26 | PXD016582 | Pride
Hla class i peptide ligands  colorectal cancer  tumor heterogeneity  patient-derived organoids  mass spectrometry  affinity proteomics 
Sort   by:  
 Page size